Published in Drug Week, November 9th, 2001
Fusion inhibitors are part of a broader class of antiviral agents collectively referred to as entry inhibitors that block binding to or fusion with target cells.
Under the terms of the agreement, Roche and Trimeris will immediately begin using ViroLogic's newly developed proprietary entry inhibitor assays to evaluate their investigational HIV drugs, T-20,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.